Table 2.
Patient and tumor characteristics of the total cohort and by PIK3CA mutation status.
| Characteristic | Total cohort (N = 312) |
Wild type (N= 233) |
PIK3CA Mutated (N = 79) |
P value* | |
|---|---|---|---|---|---|
| N (%) | N (%) | N (%) | |||
| Age | |||||
| ≤ 50 | 130 (42%) | 106 (45%) | 24 (30%) | ||
| > 50 | 164 (53%) | 113 (48%) | 51 (65%) | 0.014 | |
| Unknown | 18 (6%) | 14 (1%) | 4 (1%) | ||
| Menopausal status | |||||
| Pre | 84 (27%) | 66 (28%) | 18 (23%) | ||
| Post | 77 (25%) | 51 (22%) | 26 (33%) | 0.079 | |
| Unknown | 151 (49%) | 116 (50%) | 35 (44%) | ||
| Race | |||||
| Caucasian | 268 (86%) | 197 (85%) | 71 (90%) | ||
| Black | 27 (9%) | 24 (10%) | 3 (4%) | ||
| Asian/Pacific Islander | 2 (1%) | 2 (0.1%) | 0 (0%) | 0.178 | |
| Unknown or other | 15 (5%) | 10 (4%) | 4 (5%) | ||
| Tumor size | |||||
| 0 – 2 cm | 76 (24%) | 58 (25%) | 18 (23%) | ||
| 2.1 – 5 cm | 75 (24%) | 56 (24%) | 19 (24%) | ||
| > 5 cm | 19 (6%) | 16 (7%) | 3 (4%) | 0.74 | |
| Unknown or NA | 142 (46%) | 103 (44%) | 39 (49%) | ||
| Positive lymph nodes | |||||
| 0 | 107 (34%) | 75 (32%) | 32 (41%) | ||
| 1 – 3 | 91 (29%) | 71 (30%) | 20 (25%) | ||
| > 3 | 65 (21%) | 50 (21%) | 15 (19%) | 0.39 | |
| NA | 49 (16%) | 37 (16%) | 12 (15%) | ||
| Histologic subtype | |||||
| Ductal | 283 (91%) | 211 (93%) | 72 (92%) | ||
| Lobular | 12 (4%) | 8 (4%) | 4 (5%) | ||
| Other | 17 (5%) | 8 (4%) | 2 (3%) | 0.74 | |
| Histologic Grade | |||||
| Low | 40 (13%) | 23 (10%) | 17 (22%) | ||
| Intermediate | 122 (39%) | 80 (34%) | 42 (53%) | ||
| High | 143 (46%) | 124 (53%) | 19 (24%) | < 0.001 | |
| Unknown or NA | 7 (2%) | 6 (3%) | 1 (1%) | ||
| ER | |||||
| Postive | 208 (67%) | 142 (61%) | 66 (84%) | ||
| Negative | 93 (30%) | 85 (36%) | 8 (8%) | < 0.001 | |
| Unknown | 11 (4%) | 6 (3%) | 5 (6%) | ||
| PR | |||||
| Positive | 175 (56%) | 119 (51%) | 56 (71%) | ||
| Negative | 122 (39%) | 105 (45%) | 17 (22%) | <0.001 | |
| Unknown | 15 (5%) | 9 (4%) | 6 (8%) | ||
| HER2 | |||||
| Positive | 52 (17%) | 47 (20%) | 6 (8%) | ||
| Negative | 233 (75%) | 171 (73%) | 62 (78%) | 0.008 | |
| Intedeterminate or unknown | 26 (8%) | 15 (6%) | 11 (14%) | ||
| Receptor status | |||||
| ER+ or PR+/HER2− | 169 (54%) | 113 (48%) | 56 (71%) | ||
| ER+ or PR+/HER2+ | 30 (10%) | 27 (12%) | 3 (4%) | ||
| ER−and PR−/HER2+ | 21 (7%) | 19 (8%) | 2 (3%) | ||
| ER−and PR−/HER2− | 64 (21%) | 58 (25%) | 6 (8%) | ||
| Other | 28 (9%) | 16 (7%) | 12 (15%) | < 0.001 | |
| Clinical trial participant | |||||
| yes | 82 (26%) | 57 (24%) | 25 (32%) | ||
| no | 227 (73%) | 173 (74%) | 54 (68%) | 0.23 | |
| Unknown | 3 (1%) | 3 (1%) | 0 (0%) | ||
| PI3K specific trial | |||||
| yes | 40 (13%) | 17 (7%) | 23 (29%) | ||
| no | 42 (13%) | 40 (17%) | 2 (3%) | <0.001 | |
| NA | 230 (74%) | 176 (76%) | 54 (68%) | ||
| Recurrent disease | |||||
| yes | 195 (63%) | 134 (58%) | 61 (77%) | ||
| no | 117 (38%) | 99 (42%) | 18 (23%) | 0.002 | |
| Metastatic at diagnosis | |||||
| yes | 44 (14%) | 29 (12%) | 15 (19%) | ||
| no | 266 (85%) | 202 (87%) | 64 (81%) | 0.16 | |
| Unknown | 2 (1%) | 2 (0.1%) | 0 (0%) | ||
Note: "Unknown," "other," or "NA" not included in p value calculation.